Tonix Pharmaceuticals Holding (TNXP) Equity Average (2023 - 2025)
Historic Equity Average for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $199.6 million.
- Tonix Pharmaceuticals Holding's Equity Average rose 24316.08% to $199.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.6 million, marking a year-over-year increase of 24316.08%. This contributed to the annual value of $122.5 million for FY2024, which is N/A changed from last year.
- Per Tonix Pharmaceuticals Holding's latest filing, its Equity Average stood at $199.6 million for Q3 2025, which was up 24316.08% from $174.2 million recorded in Q2 2025.
- Over the past 5 years, Tonix Pharmaceuticals Holding's Equity Average peaked at $199.6 million during Q3 2025, and registered a low of $58.2 million during Q3 2024.
- Over the past 3 years, Tonix Pharmaceuticals Holding's median Equity Average value was $121.9 million (recorded in 2023), while the average stood at $127.8 million.
- In the last 5 years, Tonix Pharmaceuticals Holding's Equity Average tumbled by 5548.57% in 2024 and then soared by 24316.08% in 2025.
- Over the past 3 years, Tonix Pharmaceuticals Holding's Equity Average (Quarter) stood at $113.2 million in 2023, then decreased by 5.56% to $106.9 million in 2024, then surged by 86.72% to $199.6 million in 2025.
- Its Equity Average stands at $199.6 million for Q3 2025, versus $174.2 million for Q2 2025 and $160.0 million for Q1 2025.